Androgen metabolism in patients with benign prostatic hypertrophy.
D000328:Adult; D000368:Aged; D000375:Aging; D000728:Androgens / Q000378:metabolism*; D015113:Androstane-3,17-diol / Q000378:metabolism; D000731:Androstanes / Q000378:metabolism; D000735:Androstenedione / Q000378:metabolism; D000738:Androsterone / Q000031:analogs & derivatives; D000818:Animals; D001798:Blood Proteins / Q000378:metabolism; D003534:Cyproterone / Q000627:therapeutic use; D013196:Dihydrotestosterone / Q000378:metabolism; D004958:Estradiol / Q000378:metabolism; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009132:Muscles / Q000378:metabolism; D011372:Progestins / Q000627:therapeutic use; D011467:Prostate / Q000378:metabolism; D011470:Prostatic Hyperplasia / Q000188:drug therapy / Q000378:metabolism*; D011485:Protein Binding; D013739:Testosterone / Q000378:metabolism
D000728:Androgens; D000731:Androstanes; D001798:Blood Proteins; D004967:Estrogens; D011372:Progestins; D013196:Dihydrotestosterone; D015113:Androstane-3,17-diol; D013739:Testosterone; D000735:Androstenedione; D004958:Estradiol; D000738:Androsterone; D003534:Cyproterone